Alnylam Pharmaceuticals, Inc. $ALNY Stake Lowered by Bank of New York Mellon Corp

Bank of New York Mellon Corp cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 60.3% in the 4th quarter, Holdings Channel reports. The firm owned 504,133 shares of the biopharmaceutical company’s stock after selling 765,650 shares during the period. Bank of New York Mellon Corp’s holdings in Alnylam Pharmaceuticals were worth $200,469,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ALNY. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares during the period. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 0.4% in the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after purchasing an additional 31,184 shares in the last quarter. Groupama Asset Managment increased its holdings in Alnylam Pharmaceuticals by 160.4% during the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after buying an additional 2,483,697 shares during the last quarter. Geode Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after buying an additional 151,480 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $895,816,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the topic of several research reports. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Canaccord Genuity Group lifted their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a research note on Friday, May 1st. Finally, Royal Bank Of Canada cut their target price on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Alnylam Pharmaceuticals Stock Down 0.2%

NASDAQ ALNY opened at $303.05 on Friday. The stock’s 50-day moving average price is $307.66 and its 200-day moving average price is $349.36. The company has a market capitalization of $40.46 billion, a P/E ratio of 82.80 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a 52 week low of $283.10 and a 52 week high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company posted ($0.44) EPS. The company’s revenue was up 96.4% compared to the same quarter last year. On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 7,740 shares of company stock worth $2,420,214 over the last ninety days. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.